Insider · CIK 0001815308
Brian Piekos
cfoofficer
Files at KALV (KalVista Pharmaceuticals, Inc.). First filing Nov 26, 2025, latest Nov 26, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $60k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 39Weak | KalVista Pharmaceuticals, Inc. | $60k 4,471 shares | -30% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 21, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Common Stock | +15,000 | - | - | 15,000 | Nov 26, 2025 |
| Nov 24, 2025 | KALV KalVista Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -4,471 | $13.45 | $60k | 10,529 | Nov 26, 2025 |
| Nov 21, 2025 | KALV KalVista Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitderivative | -15,000 | $0.00 | $0 | 65,000 | Nov 26, 2025 |
| Feb 21, 2025 | KALV KalVista Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitderivative | +80,000 | $0.00 | $0 | 80,000 | Feb 25, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.